Calcineurin inhibitor-related cholestasis complicating lung transplantation.
case_report · Level V
Where this comes from
- Record sourced from PubMed, PMID 20417810.
- Also identified by DOI 10.1016/j.athoracsur.2009.09.081.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Hepatotoxicity, including cholestasis, is a rare but significant complication of treatment with calcineurin inhibitors. Timely life-saving therapy with revision of immunosuppression is mandatory. A 43-year-old woman with pulmonary hypertension was found to have severe cholestasis (serum bilirubin up to 35 mg/dL) after a living-donor lobar lung transplantation. Calcineurin-inhibitor cholestasis markedly improved after withdrawal of the calcineurin inhibitor, initiation of sirolimus, and interleukin-2 receptor blockade. Awareness of the diagnostic criteria of this rare posttransplant complication is important to initiate timely therapy.
Medical subject headings
- Calcineurin Inhibitors
- Cholestasis
- Hypertension, Pulmonary
- Immunosuppressive Agents
- Lung Transplantation